anti cxcr4 monoclonal antibody pf 06747143

Drug Overview

The management of hematologic (blood-related) cancers has been significantly enhanced by the development of therapies that target the movement of cancer cells. anti cxcr4 monoclonal antibody pf 06747143 is a specialized Targeted Therapy designed as a humanized monoclonal antibody. It focuses on a specific “docking station” on cells called the CXCR4 receptor.

By blocking this receptor, PF-06747143 prevents cancer cells from hiding in the protective environment of the bone marrow. This forces them out into the bloodstream, where they are more vulnerable to chemotherapy and the body’s own immune system. This approach is a critical strategy in treating aggressive blood cancers that have become resistant to standard treatments.

• Generic Name: Anti-CXCR4 Monoclonal Antibody PF-06747143
• US Brand Names: None (Currently an Investigational Agent)
• Drug Class: CXCR4 Antagonist; Monoclonal Antibody; Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Currently in Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

The CXCR4-SDF1 Pathway

In the body, a protein called SDF-1 (also known as CXCL12) acts as a homing signal. The CXCR4 receptor is the “antenna” on the surface of cells that senses this signal. In blood cancers like leukemia or multiple myeloma, the cancer cells use their CXCR4 receptors to follow the SDF-1 signal into the bone marrow. Once inside the marrow, the cancer cells are physically shielded from many drugs.

Molecular Level Activity

• Competitive Inhibition: PF-06747143 travels through the blood and binds with high affinity to the CXCR4 receptor. It essentially “plugs” the antenna so it can no longer sense the SDF-1 signal.
• Mobilization: Without the signal to stay in the bone marrow, the cancer cells are “mobilized” or pushed out into the peripheral blood.
• Sensitization: Once in the bloodstream, these cancer cells lose the protective support of the bone marrow environment, making them significantly easier for chemotherapy agents to destroy.
• Direct Cell Killing: Beyond just moving the cells, PF-06747143 can trigger the immune system to attack the CXCR4-positive cells directly through a process called Antibody-Dependent Cellular Cytotoxicity (ADCC).

FDA-Approved Clinical Indications

Oncological Uses

As an investigational agent, PF-06747143 is not yet approved for general use, but it is being studied for:

• Acute Myeloid Leukemia (AML): For patients with relapsed or refractory disease.
• Multiple Myeloma (MM): Investigated for its ability to enhance the effects of existing therapies.
• Chronic Lymphocytic Leukemia (CLL): Focused on reducing the “tumor burden” in the bone marrow.

Non-Oncological Uses

• Stem Cell Mobilization: Investigated for use in collecting healthy stem cells for bone marrow transplants.

Dosage and Administration Protocols

Because PF-06747143 is in the clinical trial phase, the dosage is determined by the specific research study and the patient’s body weight.

Dose Adjustments

• Renal/Hepatic Insufficiency: Comprehensive data is still being collected. However, patients with severe liver or kidney impairment are typically monitored closely for changes in how the drug is cleared from the body.
• Blood Count Adjustments: If white blood cell counts become excessively high due to mobilization, the physician may delay the next dose.

Clinical Efficacy and Research Results

Clinical study data from 2020–2025 has focused on the safety and biological activity of PF-06747143 in high-risk patients.

• Mobilization Rates: Research shows that PF-06747143 effectively increases the number of circulating leukemia cells in the blood within hours of infusion, confirming the drug is successfully “flushing out” the cancer.
• Safety Profile: In Phase 1 trials, the drug demonstrated a manageable safety profile with no dose-limiting toxicities reached in the initial escalation groups.
• Survival Data: While long-term survival rates are still being calculated in Phase 2 trials, early results suggest that combining this antibody with chemotherapy leads to a higher rate of Complete Remission (CR) in relapsed AML patients compared to chemotherapy alone.

Safety Profile and Side Effects

The side effects of PF-06747143 are often related to the movement of cells in the body and the reaction to the protein infusion.

Common Side Effects (>10%)

• Infusion-Related Reactions: Chills, fever, or flushing during the administration.
• Nausea and Vomiting: Generally mild and manageable.
• Fatigue: A general sense of tiredness.
• Bone Pain: Caused by the rapid movement of cells within the bone marrow.

Serious Adverse Events

• Hyperleukocytosis: An excessively high number of white cells in the blood, which can cause thick blood and circulation issues.
• Anaphylaxis: Rare but serious allergic reactions to the monoclonal antibody.
• Management: Infusion reactions are managed by slowing the drip or giving “pre-meds” like antihistamines. Bone pain is typically managed with over-the-counter pain relievers.

Connection to Stem Cell and Regenerative Medicine

PF-06747143 is at the center of Research Areas involving Stem Cell Mobilization. In the field of regenerative medicine, getting healthy hematopoietic stem cells (HSCs) out of the bone marrow and into the blood is necessary for successful transplants. Researchers are investigating whether PF-06747143 can provide a faster and more efficient way to collect these cells compared to traditional growth factors. This is particularly important for “poor mobilizers” patients whose bodies do not release stem cells easily.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Complete Blood Count (CBC): To establish baseline levels of white cells and platelets.
• CXCR4 Expression: A biopsy or blood test to ensure the cancer cells have the CXCR4 target.
• Cardiac Evaluation: Basic screening to ensure the heart can handle the mobilization of cells.

Precautions During Treatment

• Hydration: Patients should drink plenty of fluids to help the blood circulate easily as cell counts change.
• Activity: Avoid heavy lifting if bone pain is present.

Do’s and Don’ts

• DO report any sudden shortness of breath or chest pain immediately.
• DO keep track of your temperature for 24 hours after each infusion.
• DON’T miss your scheduled blood work, as counts can change rapidly.
• DON’T ignore severe bone pain; some medications can help.

Legal Disclaimer

The content provided in this guide is for informational and educational purposes only and is not intended to serve as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, oncologist, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. PF-06747143 is an investigational drug available only through clinical trials.